Enabling Cutting-Edge Technologies That Will Help Shape Our Future

​2123 Frontiers uses our research, experts, and gatherings to take a systems approach to “enable” current cutting-edge technologies in science, engineering, medicine and technology.

Defining a frontier or breakthrough is no easy feat, but at its core, we believe these are “significant” advancements with the potential to create a positive impact on humanity. Honestly, some of them will work, and many may not. Some will be quick; some will take decades. The most important thing is to have the aspiration to change the trajectory of societal impact.

We believe this magic happens at the intersection of science, medicine, business, and engineering, driven by leaders who have the boldness, resilience, and persistence to push the envelope on new frontiers and drive breakthroughs!! Our platform brings together driven entrepreneurs, innovators, pioneers, and visionaries, all with a common purpose — “enabling” breakthroughs as we collectively push society’s frontiers.

Our Frontiers

Healthcare & Life Sciences

The pace of medical innovation continues to accelerate with new ideas being pursued. Scientists are focused on several major areas of unmet need from rare diseases (Huntington’s disease, sickle cell anemia) to neurological conditions (Alzheimer's, Parkinson's, Epilepsy) to oncology (pancreatic cancer, lung cancer, colorectal cancer) and metabolic health (diabetes, obesity, hormonal conditions).

Scientists have been making significant progress on many new tools and foundational capabilities e.g. gene editing, pharmacogenomics, personalized medicine, predictive analysis, novel biomarkers, implantable/wearable devices, tissue cell engineering. These new diagnostics, devices, drugs, and software/AI will allow us to better tackle some of the most impactful diseases in medicine.

We want to enable innovators, scientists, physicians, investors and entrepreneurs to accelerate the pace of medical innovation for humanity.

High Tech

Solutions that improve data structure, data architecture models, and data related technologies such as generative AI, large language models, cloud-native data, real time data processing are foundational.

Advancement in computation such as hardware advancement (quantum computing, semiconductors), software, and algorithms (high performance computing, quantum algorithms) are enabling the processing of larger amounts of data.

Spatial computing, Augmented reality (AR), Virtual reality (VR) and mixed reality is considered the next big paradigm shift in computing, enabling human-computer interaction to take place in the real world, in and around natural bodies and physical environments.

Innovations in robotics such as soft robotics, autonomous systems, human-robot interactions, bio-inspired robotics and AI and robotics integration have wide-ranging applications in a variety of industries such as healthcare, manufacturing, education.

To enable the secure implementation of technology, advances in cybersecurity tools such as zero trust architecture, next generation cloud workforce protection, password-less authentication, blockchain, quantum computing as well as ethical and legal guidelines must be put into place.

All these innovations will contribute to transformation in every industry and bringing us closer to a reality once only imagined!

Company Spotlight: Aveta Biomics

Overview: Aveta Biomics, founded in 2013, is dedicated to unlocking the power of nature-inspired drugs to transform cancer treatment, aiming for durable responses and global accessibility. Their unique Orthologous Molecular Structures (OMS) platform leverages evolutionary biology to create multi-targeted, synergistic therapies that "reset" dysregulated processes in cancer cells with minimal toxicity.

Their lead candidate, APG-157, is a first-in-class, orally administered neoadjuvant therapy advancing into Phase 3 studies for newly diagnosed, locally advanced Head and Neck cancer (LA-HNC). Results from their Phase 2A study in 24 LA-HNC patients were highly promising with APG-157 demonstrating Exceptional Safety, Tumor Control and Durable Benefit. Phase 1 data also indicates APG-157 could reverse oral microbiome dysbiosis in cancer subjects.

Leadership:  Parag Mehta, CEO; Luis Avila, CSO; Selda Samakoglu, CMO and Robert Charnas, SVP Regulatory Affairs.

Financials:  Research activities funded so far by Aveta Biomics and non-dilutive funding from partner institutions. Now raising funds to power Phase 2B/3 study leading to accelerated approval of their lead candidate.

Key Milestones: 

  • Completed Phase 2A Neoadjuvant HNC study in early 2025, with interim Event-Free Survival (EFS) data cut as of June 2, 2025.

  • Presented a poster at ASCO 2025. Neoadjuvant APG-157 monotherapy in patients with locally advanced squamous cell carcinoma of head and neck: A phase IIA, Single Arm Trial.

  • Plan to present detailed translational data at ESMO 2025 in October.

Near-Term Priorities: 

  • Secure licensing partnerships. 

  • Prepare to start registrational trial in Q1 ’26 at sites across US, Europe, Africa and Asia.